Our results showed a significant suppression of tumour growth in mice receiving USP22 knockout tumours, particularly under Sorafenib treatment, as evident from the reduced tumour volume and weight in the USP22‐depleted groups (Figure 8B,C). This evidence concerns the gene USP22 and neoplasm.